1
Home
Companies

Immuneering

#8846

Rank

$152.58M

Marketcap

US United States

Country

Immuneering
Leadership team

Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. (Co-Founder, Pres, CEO & Director)

Dr. Brett M. Hall Ph.D. (Chief Scientific Officer)

Ms. Mallory Morales CPA (VP of Fin., Principal Financial & Accounting Officer and Treasurer)

Products/ Services
Biotechnology, Medical, Pharmaceutical
Number of Employees
50 - 100
Headquarters
Cambridge, Massachusetts, United States
Established
2008
Company Registration
SEC CIK number: 0001790340
Revenue
500K - 2M
Traded as
IMRX
Social Media
URL
https://immuneering.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
History

Immuneering Co. was founded in 2018 by CEO Rich Berliner and CTO Dan Sommer with a vision to improve the diagnosis and treatment of human diseases by placing machine learning, analytics, and precision medicine tools in the hands of physicians and researchers.

Mission
At Immuneering Co., our mission is to use data and analytics to transform healthcare and empower patients and providers to make precise decisions about health and wellness.
Vision
Our vision is to improve the lives of people by using data science and advanced analytics to identify and improve disease outcomes.
Key Team

Ms. Paula George CPA (Sr. Mang. of Accounting & Operations)

Dr. Peter King Ph.D. (Head of Discovery & VP)

Mr. Michael D. Bookman J.D. (Gen. Counsel & Sec.)

Dr. Rajaraman Krishnan Ph.D. (Head of Neuroscience Discovery)

Ms. Leah R. Neufeld (Chief People Officer)

Dr. Scott Barrett M.D. (Chief Medical Officer)

Dr. Mohamedi Kagalwala M.B.A., Ph.D. (Head of Neuroscience Devel.)

Recognition and Awards
Immuneering Co. was named one of the 10 Breakthrough 10 Companies of 2020 by Fast Company and was also a winner of the 2017 Forbes AI 50 Top Artificial Intelligence Companies in Healthcare. Immuneering Co. also recently received funding from leading healthcare venture investors including Foresite Capital and The Westly Group.
References

https://in.investing.com/equities/immuneering

https://finance.yahoo.com/quote/IMRX/profile?p=IMRX

https://www.crunchbase.com/organization/immuneering-inc

https://companiesmarketcap.com/

https://immuneering.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Immuneering
Leadership team

Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. (Co-Founder, Pres, CEO & Director)

Dr. Brett M. Hall Ph.D. (Chief Scientific Officer)

Ms. Mallory Morales CPA (VP of Fin., Principal Financial & Accounting Officer and Treasurer)

Products/ Services
Biotechnology, Medical, Pharmaceutical
Number of Employees
50 - 100
Headquarters
Cambridge, Massachusetts, United States
Established
2008
Company Registration
SEC CIK number: 0001790340
Revenue
500K - 2M
Traded as
IMRX
Social Media
URL
https://immuneering.com